New weapon against superbug pneumonia enters human testing
NCT ID NCT07492771
First seen Mar 28, 2026 · Last updated May 07, 2026 · Updated 3 times
Summary
This early-stage study tests a new drug called MP101 in 18 adults with a serious lung infection caused by Pseudomonas aeruginosa bacteria. The drug is given once through a vein along with standard antibiotics. The main goal is to check if MP101 is safe and tolerable, and to see how the body processes it. This is a first step to see if MP101 could help when standard antibiotics aren't working well.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA, BACTERIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance Hospital
Seoul, Seodaemun-gu, 03722, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.